Japanese Biotech Chugai Grants Exclusive VEGF-D Global License To Circadian Subsidiary Vegenics
This article was originally published in PharmAsia News
Australian Circadian Technologies announced Jan. 13 that Chugai Pharmaceutical Co. has granted an exclusive, global license to its VEGF-D intellectual property to Circadian subsidiary Vegenics
You may also be interested in...
The company has secured four cornerstone investors to purchase shares together worth $550 million, with total net proceeds from the global offering possibly reaching as high $2.46 billion.
A regular roundup of commercial stories appearing in Scrip’s sister publication PharmAsia News, whose multilingual team of regional experts provides authoritative business intelligence focused on the Asian marketplace. Full stories can be accessed by clicking on the story title (subscription required).